JP2003510257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003510257A5 JP2003510257A5 JP2001525222A JP2001525222A JP2003510257A5 JP 2003510257 A5 JP2003510257 A5 JP 2003510257A5 JP 2001525222 A JP2001525222 A JP 2001525222A JP 2001525222 A JP2001525222 A JP 2001525222A JP 2003510257 A5 JP2003510257 A5 JP 2003510257A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- lys
- asn
- arg
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 14
- -1 N-dimethyl-Lys Inorganic materials 0.000 description 10
- 208000031225 myocardial ischemia Diseases 0.000 description 7
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 6
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 6
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 6
- 229960003104 ornithine Drugs 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 230000010410 reperfusion Effects 0.000 description 5
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 4
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 4
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- 102220547842 Apoptosis-associated speck-like protein containing a CARD_L12A_mutation Human genes 0.000 description 2
- 102220547742 Apoptosis-associated speck-like protein containing a CARD_Q10A_mutation Human genes 0.000 description 2
- 102220485509 Golgi phosphoprotein 3-like_R18A_mutation Human genes 0.000 description 2
- 101710183654 Keratin, type I cytoskeletal 25 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102220479923 Leucine-rich repeat-containing protein 26_H11A_mutation Human genes 0.000 description 2
- 102220550712 Myocardin_S17A_mutation Human genes 0.000 description 2
- 102220642281 PTB domain-containing engulfment adapter protein 1_D13A_mutation Human genes 0.000 description 2
- 102220642319 PTB domain-containing engulfment adapter protein 1_D14A_mutation Human genes 0.000 description 2
- 102220607774 TYRO protein tyrosine kinase-binding protein_R22A_mutation Human genes 0.000 description 2
- 102220610855 Thialysine N-epsilon-acetyltransferase_K19A_mutation Human genes 0.000 description 2
- 102220470368 Thymosin beta-10_K25A_mutation Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102220319377 rs769687105 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15513599P | 1999-09-22 | 1999-09-22 | |
| US60/155,135 | 1999-09-22 | ||
| US21943800P | 2000-07-20 | 2000-07-20 | |
| US60/219,438 | 2000-07-20 | ||
| PCT/US2000/025827 WO2001021648A1 (en) | 1999-09-22 | 2000-09-21 | Uses of kappa-conotoxin pviia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003510257A JP2003510257A (ja) | 2003-03-18 |
| JP2003510257A5 true JP2003510257A5 (enExample) | 2007-11-01 |
Family
ID=26852034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001525222A Pending JP2003510257A (ja) | 1999-09-22 | 2000-09-21 | カッパ−コノトキシンｐｖｉｉａの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040092447A1 (enExample) |
| EP (1) | EP1218407A4 (enExample) |
| JP (1) | JP2003510257A (enExample) |
| AU (1) | AU778182B2 (enExample) |
| CA (1) | CA2385047A1 (enExample) |
| WO (1) | WO2001021648A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2396529A1 (en) | 1999-12-30 | 2001-07-12 | University Of Utah Research Foundation | O-superfamily conotoxin peptides |
| AUPR506601A0 (en) * | 2001-05-17 | 2001-06-07 | Australian National University, The | Method of modulating the activity of calcium channels in cardiac cells and reagents therefor |
| CA2474316A1 (en) * | 2002-01-29 | 2003-08-07 | Cognetix, Inc. | Kappa-pviia-related conotoxins as organ protectants |
| US20040229780A1 (en) * | 2002-09-20 | 2004-11-18 | Olivera Baldomero M. | KappaM-conopeptides as organ protectants |
| US20060178303A1 (en) * | 2004-09-09 | 2006-08-10 | University Of Utah Research Foundation | Potassium channel blockers |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| WO2016049873A1 (zh) * | 2014-09-30 | 2016-04-07 | 深圳华大基因科技有限公司 | 芋螺毒素多肽κ-CPTx-btl03、其制备方法及应用 |
| US10087216B2 (en) * | 2014-09-30 | 2018-10-02 | Bgi Shenzhen Co., Limited | Conotoxin polypeptide κ-CPTx-bt101, and method for preparation thereof and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672682A (en) * | 1996-03-18 | 1997-09-30 | University Of Utah Research Foundation | Conotoxin peptide PVIIA |
| US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
-
2000
- 2000-09-21 CA CA002385047A patent/CA2385047A1/en not_active Abandoned
- 2000-09-21 JP JP2001525222A patent/JP2003510257A/ja active Pending
- 2000-09-21 WO PCT/US2000/025827 patent/WO2001021648A1/en not_active Ceased
- 2000-09-21 AU AU75968/00A patent/AU778182B2/en not_active Ceased
- 2000-09-21 EP EP00965219A patent/EP1218407A4/en not_active Withdrawn
-
2003
- 2003-07-28 US US10/627,685 patent/US20040092447A1/en not_active Abandoned
-
2005
- 2005-10-27 US US11/259,039 patent/US20060040312A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100248030B1 (ko) | 시토킨 조절제 및 시토킨 농도 변화에 관련된 병변 및 질환에 있어서 그의 용도 | |
| US5446130A (en) | Parathyroid hormone antagonists | |
| DK2473518T3 (en) | Stabilized melanocortin ligands | |
| US5786332A (en) | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels | |
| JPS62500871A (ja) | 薬理活性を有するジペプチド化合物及びそれを含む組成物 | |
| CA2596597A1 (en) | Method for stimulation collagen synthesis and/or kgf expression | |
| AU599177B2 (en) | 2,3-disubstituted isoxazolidines, a process for their preparation, agents containing them, and their use | |
| JP2003510257A5 (enExample) | ||
| EP1485345B1 (de) | Hemmstoffe der urokinase, ihre herstellung und verwendung | |
| LV10108B (en) | Inhibitors of cells proliferation, pharmaceutical composition, process of producing of compounds, methods of inhibition of cellular proliferation | |
| US6057295A (en) | Oligopeptides derived from C-reactive protein fragments | |
| JP2003528814A5 (enExample) | ||
| JPWO1995018147A1 (ja) | オーレオバシジン類 | |
| JP2003501109A5 (enExample) | ||
| WO2011060018A2 (en) | Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives | |
| JP5689892B2 (ja) | ２−アミノ−３−メチル−ヘキサ−５エン酸、及びバシトラシン等のペプチドの生成におけるその使用方法 | |
| CA2719940A1 (en) | Methods for treating acute myocardial infarction | |
| WO1994007518A1 (en) | Anaphylatoxin receptor ligands containing lipophilic residues | |
| Birr et al. | The hexa-and pentapeptide extension of proalbumin I. Chemical synthesis of serum albumin propeptides | |
| WO1995013302A1 (en) | Cathepsin-l-specific inhibitor polypeptide | |
| JP2007161696A (ja) | 新規なヘプタペプチド及びプロリルエンドペプチダーゼ阻害剤 | |
| AU633128B2 (en) | Anticoagulant peptides | |
| JP2017518290A (ja) | β−アレスチンエフェクターの合成 | |
| JPH08225457A (ja) | 癌転移抑制用組成物 | |
| WO1998043995A1 (en) | Novel anti-hiv complexes and medicinal compositions |